IS8255A - P38 kínasatálmar staðsettir á 5 hluta heteróhring - Google Patents

P38 kínasatálmar staðsettir á 5 hluta heteróhring

Info

Publication number: IS8255A
Authority: IS; Iceland
Prior art keywords: kinase; kinase inhibitors; disorders; compounds; heterocycle
Prior art date: 2003-06-26

Application number

IS8255A

Other languages

English (en)

Other versions

IS2916B (is

Inventor

M. Fryszman Olga

Lang Hengyuan

Lan Jiong

Chang Edcon

Fang Yunfeng

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-26

Filing date

2006-01-23

Publication date

2006-01-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34108816&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8255(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-01-23 Application filed by Novartis Ag filed Critical Novartis Ag

2006-01-23 Publication of IS8255A publication Critical patent/IS8255A/is

2014-12-15 Publication of IS2916B publication Critical patent/IS2916B/is

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Immunology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)

IS8255A 2003-06-26 2006-01-23 P38 kínasatálmar að stofni til úr 5 hluta heteróhring IS2916B (is)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US48342803P	2003-06-26	2003-06-26
US49905403P	2003-08-29	2003-08-29
US56048104P	2004-04-07	2004-04-07
PCT/US2004/020384 WO2005009973A1 (en)	2003-06-26	2004-06-24	5-membered heterocycle-based p38 kinase inhibitors

Publications (2)

Publication Number	Publication Date
IS8255A true IS8255A (is)	2006-01-23
IS2916B IS2916B (is)	2014-12-15

Family

ID=34108816

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IS8255A IS2916B (is)	2003-06-26	2006-01-23	P38 kínasatálmar að stofni til úr 5 hluta heteróhring
IS9037A IS2984B (is)	2003-06-26	2014-01-28	P38 kínasatálmar að stofni til úr 5 hluta heteróhring

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IS9037A IS2984B (is)	2003-06-26	2014-01-28	P38 kínasatálmar að stofni til úr 5 hluta heteróhring

Country Status (27)

Country	Link
US (4)	US7863314B2 (is)
EP (2)	EP1641764B1 (is)
JP (1)	JP4838121B2 (is)
KR (1)	KR101120857B1 (is)
CN (1)	CN1832928B (is)
AT (1)	ATE517872T1 (is)
AU (1)	AU2004259662B2 (is)
BR (1)	BRPI0411825B8 (is)
CA (1)	CA2526455C (is)
CY (2)	CY1111985T1 (is)
DK (2)	DK2298743T3 (is)
EC (2)	ECSP056206A (is)
ES (1)	ES2393950T3 (is)
HK (2)	HK1088895A1 (is)
HR (2)	HRP20110757T1 (is)
IL (1)	IL172182A (is)
IS (2)	IS2916B (is)
MA (1)	MA27888A1 (is)
MX (1)	MXPA05013824A (is)
MY (1)	MY158162A (is)
NO (1)	NO334947B1 (is)
NZ (1)	NZ544230A (is)
PL (2)	PL2298743T3 (is)
PT (2)	PT1641764E (is)
SI (2)	SI2298743T1 (is)
TW (2)	TWI452035B (is)
WO (1)	WO2005009973A1 (is)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7485657B2 (en)	2004-05-12	2009-02-03	Boehringer Ingelheim Pharmaceuticals, Inc.	Anti-cytokine heterocyclic compounds
BRPI0612925A2 (pt) *	2005-04-27	2010-12-07	Univ Florida Res Foudation Inc	uso de um composto, composição farmacêutica e kit
DE102005031580A1 (de) *	2005-07-06	2007-01-11	Aicuris Gmbh & Co. Kg	Substituierte Sulfolanylpyrazole und ihre Verwendung
GB0603684D0 (en) *	2006-02-23	2006-04-05	Novartis Ag	Organic compounds
MY149622A (en)	2006-03-22	2013-09-13	Hoffmann La Roche	Pyrazoles as 11-beta-hsd-1
EP2035038A4 (en) *	2006-04-03	2011-04-06	Stowers Inst For Medical Res	COMPOSITIONS AND METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE
JP2010508325A (ja) *	2006-10-30	2010-03-18	ノバルティスアーゲー	プロテインキナーゼの阻害剤として有用な３−アミノ−ピラゾール−４−カルボキサミド誘導体
GB0621978D0 (en) *	2006-11-03	2006-12-13	Chroma Therapeutics Ltd	Inhibitors of p38 mitogen-activated protein kinase
EP1992344A1 (en)	2007-05-18	2008-11-19	Institut Curie	P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
CA2694983A1 (en) *	2007-07-17	2009-01-22	Combinatorx, Incorporated	Treatments of b-cell proliferative disorders
TW200914048A (en) *	2007-07-17	2009-04-01	Combinatorx Inc	Combinations for the treatment of B-cell proliferative disorders
WO2009012482A2 (en)	2007-07-19	2009-01-22	H.Lundbeck A/S	5-membered heterocyclic amides and related compounds
US8119800B2 (en) *	2007-12-21	2012-02-21	Korea Research Institute Of Chemical Technology	Processes for preparing HIV reverse transcriptase inhibitors
DE102008015033A1 (de) *	2008-03-17	2009-09-24	Aicuris Gmbh & Co. Kg	Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
US20090281150A1 (en) *	2008-04-09	2009-11-12	Nicola Frances Bateman	Compound 249
US20100009934A1 (en) *	2008-06-09	2010-01-14	Combinatorx, Incorporated	Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
DK2313111T3 (da)	2008-08-01	2013-12-02	Ventirx Pharmaceuticals Inc	Toll-lignende receptoragonistformuleringer og anvendelse deraf
US8314090B2 (en)	2008-11-06	2012-11-20	Ventirx Pharmaceuticals, Inc.	Methods of synthesis of benzazepine derivatives
CA2770195C (en) *	2009-08-07	2015-10-13	Chugai Seiyaku Kabushiki Kaisha	Aminopyrazole derivative
US8524702B2 (en)	2009-08-18	2013-09-03	Ventirx Pharmaceuticals, Inc.	Substituted benzoazepines as toll-like receptor modulators
BR112012003757A2 (pt)	2009-08-18	2020-08-11	Ventirx Pharmaceuticals, Inc.	benzoazepinas substituídas como moduladores de receptor tipo dobre de sino
WO2011038261A1 (en) *	2009-09-24	2011-03-31	Selexagen Therapeutics, Inc.	Heterocyclic kinase inhibitors
CA2789847A1 (en) *	2010-02-15	2011-08-18	Synovo Gmbh	Kinase modulators for the treatment of cancer
CN103097358B (zh) *	2010-09-21	2015-04-08	卫材R&D管理有限公司	药物组合物
US8993631B2 (en)	2010-11-16	2015-03-31	Novartis Ag	Method of treating contrast-induced nephropathy
EP2460519A1 (en) *	2010-12-03	2012-06-06	Laboratorios Del. Dr. Esteve, S.A.	Use of sigma ligands in bone cancer pain
JP5620417B2 (ja) *	2011-02-07	2014-11-05	中外製薬株式会社	アミノピラゾール誘導体を含む医薬
SG11201404941WA (en) *	2012-03-20	2014-10-30	Novartis Ag	Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
EP3076789A4 (en) *	2013-12-04	2017-11-22	The Scripps Research Institute	Novel compounds as jnk kinase inhibitors
RU2653504C2 (ru)	2013-12-13	2018-05-10	Ф. Хоффманн-Ля Рош Аг	Ингибиторы тирозинкиназы брутона
CN105722834B (zh)	2013-12-13	2017-12-22	豪夫迈·罗氏有限公司	酪氨酸蛋白激酶抑制剂
EP3581179A1 (en)	2013-12-27	2019-12-18	Chugai Seiyaku Kabushiki Kaisha	Fgfr gatekeeper mutant gene and drug targeting same
US10479780B2 (en)	2015-06-17	2019-11-19	Chugai Seiyaku Kabushiki Kaisha	Aminopyrazole derivatives
US10214515B2 (en) *	2015-08-20	2019-02-26	Zhejiang Hisun Pharmaceutical Co., Ltd.	Substituted pyrazoles as inhibitors of fibroblast growth factor receptor
CA3016368A1 (en)	2016-03-08	2017-09-14	Mereo Biopharma 1 Limited	Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
WO2017153702A1 (en)	2016-03-08	2017-09-14	Mereo Biopharma 1 Limited	Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
GB201612240D0 (en)	2016-07-14	2016-08-31	Mereo Biopharma 1 Ltd	Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
GB201612238D0 (en) *	2016-07-14	2016-08-31	Mereo Biopharma 1 Ltd	Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
WO2018059533A1 (zh) *	2016-09-29	2018-04-05	南京明德新药研发股份有限公司	p38αMAPK激酶抑制剂及其制备方法和应用
WO2018109667A1 (en)	2016-12-15	2018-06-21	Nestec Sa	Compositions and methods that modulate white blood cells or neutrophils in a companion animal
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN114732910A (zh)	2017-10-05	2022-07-12	弗尔康医疗公司	P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
KR20200097311A (ko)	2017-12-11	2020-08-18	메레오 바이오파마 1 리미티드	만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
EP3845228A1 (en)	2017-12-11	2021-07-07	Mereo BioPharma 1 Limited	Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease
EP3773579A4 (en)	2018-03-26	2022-03-09	Clear Creek Bio, Inc.	COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
EP3563848A1 (en) *	2018-04-30	2019-11-06	S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati	Serpin inhibitors for the treatment of prion and prion-like diseases
GB201815699D0 (en) *	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
GB201815696D0 (en) *	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
GB201815695D0 (en) *	2018-09-26	2018-11-07	Mereo Biopharma 1 Ltd	Synthetic method
CN110950848B (zh) *	2018-09-27	2024-03-26	徐诺药业	新型氨基吡唑类衍生物的合成与应用
JP2022506891A (ja) *	2018-11-13	2022-01-17	ノバルティスアーゲー	Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物
CN112778333B (zh) *	2021-01-23	2022-07-05	中国科学院新疆理化技术研究所	一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1152421B (de)	1961-03-21	1963-08-08	Bayer Ag	Verfahren zur Herstellung von 4-Hydroxy-pyrazolo[3, 4-b]chinolinen
JPS5111499Y2 (is)	1971-04-22	1976-03-27
USRE28819E (en)	1972-12-08	1976-05-18	Syntex (U.S.A.) Inc.	Dialkylated glycol compositions and medicament preparations containing same
JPS5527916B2 (is)	1973-02-05	1980-07-24
JPS51112341A (en)	1975-02-24	1976-10-04	Konishiroku Photo Ind Co Ltd	Magenta dye image formation
US4200750A (en)	1977-01-07	1980-04-29	Westwood Pharmaceuticals Inc.	4-Substituted imidazo [1,2-a]quinoxalines
AU690527B2 (en)	1992-12-17	1998-04-30	Pfizer Inc.	Pyrazoles having CRF antagonist activity
US6103900A (en) *	1992-12-17	2000-08-15	Pfizer Inc	Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
US6005109A (en) *	1997-10-30	1999-12-21	Pflizer Inc.	Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
US5514643A (en)	1993-08-16	1996-05-07	Lucky Ltd.	2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms
US5646152A (en)	1994-06-15	1997-07-08	Pfizer Inc.	Methods of administering CRF antagonists
CA2163399A1 (en)	1994-11-24	1996-05-25	Katsuhiro Kawano	Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
DE19518054A1 (de)	1995-03-08	1996-09-12	Hoechst Schering Agrevo Gmbh	N-Arylpyrazolketone und deren Derivate, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
US5658903A (en)	1995-06-07	1997-08-19	Smithkline Beecham Corporation	Imidazole compounds, compositions and use
US5977103A (en)	1996-01-11	1999-11-02	Smithkline Beecham Corporation	Substituted imidazole compounds
US5945418A (en)	1996-12-18	1999-08-31	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
US6147080A (en)	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
SK86699A3 (en)	1996-12-23	2000-11-07	Du Pont Pharm Co	Nitrogen containing heteroaromatics as factor xa inhibitors
US6087496A (en)	1998-05-22	2000-07-11	G. D. Searle & Co.	Substituted pyrazoles suitable as p38 kinase inhibitors
BR9809451A (pt)	1997-05-22	2000-06-20	Searle & Co	Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
CA2295762A1 (en)	1997-07-02	1999-01-14	Ravi Shanker Garigipati	Novel cycloalkyl substituted imidazoles
DE69835241T2 (de)	1997-10-27	2007-05-31	Agouron Pharmaceuticals, Inc., La Jolla	4-Aminothiazol Derivate, deren Herstellung und deren Verwendung als Inhibitoren Cyclin-abhängiger Kinasen
JP3590586B2 (ja) *	1998-05-05	2004-11-17	エフ．ホフマン−ラロシュアーゲー	Ｐ−３８ｍａｐキナーゼインヒビターとしてのピラゾール誘導体
US6376527B1 (en)	1998-05-05	2002-04-23	Syntex (U.S.A.) Llc	Pyrazole derivatives-p38 map kinase inhibitors
US6316466B1 (en)	1998-05-05	2001-11-13	Syntex (U.S.A.) Llc	Pyrazole derivatives P-38 MAP kinase inhibitors
US20020156114A1 (en)	1998-05-05	2002-10-24	Goldstein David Michael	Pyrazole derivatives - p38 MAP kinase inhibitors
US6130235A (en)	1998-05-22	2000-10-10	Scios Inc.	Compounds and methods to treat cardiac failure and other disorders
CN1261098C (zh)	1998-08-28	2006-06-28	西奥斯股份有限公司	p38－α激酶的抑制剂
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
JP2002528499A (ja)	1998-10-29	2002-09-03	ブリストル−マイヤーズスクイブカンパニー	Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物
GB9906566D0 (en)	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
PL215901B1 (pl)	1999-04-15	2014-02-28	Bristol Myers Squibb Co	Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
GB9924092D0 (en)	1999-10-13	1999-12-15	Zeneca Ltd	Pyrimidine derivatives
CN1255406C (zh)	1999-11-10	2006-05-10	奥索-麦克尼尔药品公司	取代的2－芳基－3－(杂芳基)－咪唑并[1，2－a]嘧啶类化合物以及相关的药物组合物和方法
AU2001230026A1 (en)	2000-02-04	2001-08-14	Novo-Nordisk A/S	2,4-diaminothiazole derivatives
EP1320365A4 (en)	2000-09-21	2004-03-17	Bristol Myers Squibb Co	SUBSTITUTED AZOLE DERIVATIVES AS AN INHIBITOR OF THE CORTICOTROPIN RELEASE FACTOR
JP2004522713A (ja)	2000-11-17	2004-07-29	ブリストル−マイヤーズ　スクイブ　カンパニー	ｐ３８キナーゼ関連疾患の処置方法およびキナーゼインヒビターとして有用なピロロトリアジン化合物
WO2002057101A2 (en)	2001-01-17	2002-07-25	Boyean Kim	Sun visor having office work apparatus
US6756374B2 (en)	2001-01-22	2004-06-29	Hoffmann-La Roche Inc.	Diaminothiazoles having antiproliferative activity
JP2004536057A (ja)	2001-05-11	2004-12-02	バーテックス　ファーマシューティカルズ　インコーポレイテッド	ｐ３８インヒビターとして使用する２，５−二置換ピリジン、ピリミジン、ピリダジンおよび１，２，４−トリアジンの誘導体
HN2002000156A (es)	2001-07-06	2003-11-27	Inc Agouron Pharmaceuticals	Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
GB0124934D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124939D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124933D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124941D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124932D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124931D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124928D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124936D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
RU2006126791A (ru) *	2003-12-23	2008-01-27	Новартис АГ (CH)	Бициклические гетероциклические ингибиторы р-38 киназы
JP2007084437A (ja)	2003-12-26	2007-04-05	Dai Ichi Seiyaku Co Ltd	アミノアルキルピラゾール誘導体

2004
- 2004-06-24 JP JP2006517650A patent/JP4838121B2/ja active Active
- 2004-06-24 PL PL10164367T patent/PL2298743T3/pl unknown
- 2004-06-24 TW TW093118259A patent/TWI452035B/zh not_active IP Right Cessation
- 2004-06-24 EP EP04777075A patent/EP1641764B1/en active Active
- 2004-06-24 TW TW100114024A patent/TWI449696B/zh not_active IP Right Cessation
- 2004-06-24 DK DK10164367.4T patent/DK2298743T3/da active
- 2004-06-24 MX MXPA05013824A patent/MXPA05013824A/es active IP Right Grant
- 2004-06-24 PT PT04777075T patent/PT1641764E/pt unknown
- 2004-06-24 NZ NZ544230A patent/NZ544230A/en unknown
- 2004-06-24 PT PT101643674T patent/PT2298743E/pt unknown
- 2004-06-24 BR BRPI0411825A patent/BRPI0411825B8/pt not_active IP Right Cessation
- 2004-06-24 EP EP10164367A patent/EP2298743B1/en active Active
- 2004-06-24 ES ES10164367T patent/ES2393950T3/es active Active
- 2004-06-24 SI SI200431950T patent/SI2298743T1/sl unknown
- 2004-06-24 AT AT04777075T patent/ATE517872T1/de active
- 2004-06-24 PL PL04777075T patent/PL1641764T3/pl unknown
- 2004-06-24 WO PCT/US2004/020384 patent/WO2005009973A1/en active Application Filing
- 2004-06-24 CN CN2004800180564A patent/CN1832928B/zh active Active
- 2004-06-24 AU AU2004259662A patent/AU2004259662B2/en active Active
- 2004-06-24 DK DK04777075.5T patent/DK1641764T3/da active
- 2004-06-24 CA CA2526455A patent/CA2526455C/en active Active
- 2004-06-24 SI SI200431766T patent/SI1641764T1/sl unknown
- 2004-06-24 KR KR1020057024679A patent/KR101120857B1/ko active IP Right Grant
- 2004-06-25 US US10/877,534 patent/US7863314B2/en active Active
- 2004-06-25 MY MYPI20042496A patent/MY158162A/en unknown
2005
- 2005-11-24 IL IL172182A patent/IL172182A/en active IP Right Grant
- 2005-12-08 EC EC2005006206A patent/ECSP056206A/es unknown
- 2005-12-21 MA MA28678A patent/MA27888A1/fr unknown
2006
- 2006-01-23 IS IS8255A patent/IS2916B/is unknown
- 2006-01-26 NO NO20060424A patent/NO334947B1/no unknown
- 2006-08-16 HK HK06109122.6A patent/HK1088895A1/xx unknown
- 2006-08-16 HK HK11107635.3A patent/HK1149764A1/xx not_active IP Right Cessation
2010
- 2010-11-19 US US12/950,649 patent/US8242117B2/en active Active
2011
- 2011-10-18 HR HR20110757T patent/HRP20110757T1/hr unknown
- 2011-10-27 CY CY20111101022T patent/CY1111985T1/el unknown
2012
- 2012-02-07 EC ECSP12006206 patent/ECSP12006206A/es unknown
- 2012-06-22 US US13/530,919 patent/US8410160B2/en active Active
- 2012-11-08 HR HRP20120900TT patent/HRP20120900T1/hr unknown
- 2012-11-08 CY CY20121101064T patent/CY1113313T1/el unknown
2013
- 2013-02-25 US US13/775,963 patent/US8580838B2/en active Active
2014
- 2014-01-28 IS IS9037A patent/IS2984B/is unknown

Also Published As

Publication number	Publication date
CA2526455A1 (en)	2005-02-03
ECSP056206A (es)	2006-04-19
KR20060024813A (ko)	2006-03-17
MY158162A (en)	2016-09-15
NO20060424L (no)	2006-03-15
PL1641764T3 (pl)	2011-12-30
DK2298743T3 (da)	2012-11-26
ES2393950T3 (es)	2013-01-02
WO2005009973A1 (en)	2005-02-03
NZ544230A (en)	2009-07-31
US20110071152A1 (en)	2011-03-24
HRP20110757T1 (hr)	2011-11-30
US8242117B2 (en)	2012-08-14
ATE517872T1 (de)	2011-08-15
HRP20120900T1 (hr)	2012-11-30
MXPA05013824A (es)	2006-02-28
SI1641764T1 (sl)	2011-11-30
BRPI0411825A (pt)	2006-08-08
IS2916B (is)	2014-12-15
US20050049288A1 (en)	2005-03-03
CY1113313T1 (el)	2016-04-13
TW201125854A (en)	2011-08-01
MA27888A1 (fr)	2006-05-02
CA2526455C (en)	2012-10-09
PT2298743E (pt)	2012-12-04
NO334947B1 (no)	2014-08-04
IL172182A (en)	2014-07-31
ECSP12006206A (es)	2012-03-30
TWI452035B (zh)	2014-09-11
PL2298743T3 (pl)	2013-02-28
BRPI0411825B1 (pt)	2018-11-06
HK1088895A1 (is)	2006-11-17
IS2984B (is)	2017-09-15
DK1641764T3 (da)	2011-11-21
JP2007521278A (ja)	2007-08-02
HK1149764A1 (is)	2011-10-14
TW200510328A (en)	2005-03-16
SI2298743T1 (sl)	2012-12-31
AU2004259662B2 (en)	2008-08-07
US7863314B2 (en)	2011-01-04
AU2004259662A1 (en)	2005-02-03
IS9037A (is)	2014-01-28
US20120264801A1 (en)	2012-10-18
EP1641764A1 (en)	2006-04-05
PT1641764E (pt)	2011-10-27
US8410160B2 (en)	2013-04-02
US20130172352A1 (en)	2013-07-04
EP1641764B1 (en)	2011-07-27
US8580838B2 (en)	2013-11-12
CN1832928B (zh)	2012-07-04
KR101120857B1 (ko)	2012-04-12
TWI449696B (zh)	2014-08-21
EP2298743B1 (en)	2012-08-22
EP2298743A1 (en)	2011-03-23
BRPI0411825B8 (pt)	2021-05-25
JP4838121B2 (ja)	2011-12-14
CN1832928A (zh)	2006-09-13
CY1111985T1 (el)	2015-11-04

Publication	Publication Date	Title
IS8255A (is)	2006-01-23	P38 kínasatálmar staðsettir á 5 hluta heteróhring
ATE439837T1 (de)	2009-09-15	5-gliedrige heterocyclische p-38 inhibitoren
WO2005063766A3 (en)	2005-09-09	Bicyclic heterocyclic p-38 kinase inhibitors
NO20053077D0 (no)	2005-06-23	Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
EA200700757A1 (ru)	2007-10-26	Замещённые дипиперидиновые антагонисты ccr2
IS7840A (is)	2005-05-09	3-(3,5-díoxó-4,5-díhýdró-3H-(1,2,4)tríasín-2-ýl)-bensamíð afleiður sem P2X7-hindrar til notkunar í meðferð á bólguvaldandi sjúkdómum
CY1109529T1 (el)	2014-08-13	2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων
ATE551335T1 (de)	2012-04-15	Indolylmaleimid-derivate
IS7444A (is)	2004-09-13	Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
DE60115466D1 (de)	2006-01-05	Wirkstoffvorläufer von imidazopyridin-derivaten
NO20032006D0 (no)	2003-05-05	Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
DE50307521D1 (de)	2007-08-02	Arzneimittel zur behandlung des "systemic inflammatory response syndrome"